Title: Full Text of SB2385
Official Title: 
Number of Sections: 1
Source: versions - Senate Amendment 001
Media Type: text/html

================================================================================

Section 1:
Full Text of SB2385 ILGA.GOV SB2385 - 104th General Assembly Sen. David KoehlerFiled: 5/23/2025   10400SB2385sam001LRB104 09642 BAB 26633 a1AMENDMENT TO SENATE BILL 23852    AMENDMENT NO. ______. Amend Senate Bill 2385 by replacing 3everything after the enacting clause with the following: 4    "Section 1. Short title. This Act may be cited as the 5Patient Access to Pharmacy Protection Act. 6    Section 5. Findings. The General Assembly finds that:7    (1) It is within the traditional authority of the State to 8regulate the acquisition and delivery of drugs to pharmacies 9and providers.10    (2) The federal 340B statute is silent on distribution of 11340B-acquired drugs to 340B covered entities and their 12contract pharmacy partners.13    (3) The State's compelling interest in preserving and 14improving access to health care services requires it to ensure 15that 340B covered entities continue to be allowed to contract 16with pharmacies to receive 340B drugs and dispense them to the   10400SB2385sam001- 2 -LRB104 09642 BAB 26633 a1patients of 340B covered entities in accordance with federal 2law.3    (4) Addressing accessibility of these life-saving 4medications is a matter of health, safety, and welfare for the 5people of the State of Illinois. 6    Section 10. Definitions. As used in this Act:7    "340B drug discount program" means the program established 8under Section 340B of the federal Public Health Service Act, 942 U.S.C. 256b.10    "340B contract pharmacy" means any pharmacy that is under 11contract with a 340B covered entity to dispense 340B drugs on 12behalf of the 340B covered entity and is either (i) located in 13Illinois and qualifies as a pharmacy under Section 3 of the 14Pharmacy Practice Act; or (ii) is located in a state, 15commonwealth, or territory of the United States, other than 16Illinois, and dispenses 340B drugs on behalf of the 340B 17covered entity.18    "340B covered entity" means an entity in Illinois that 19qualifies as a covered entity under Section 340B of the 20federal Public Health Service Act, 42 U.S.C. 256b(a)(4).21    "340B drug" means a drug that has been subject to any offer 22for reduced prices by a manufacturer pursuant to 42 U.S.C. 23256b and is purchased by a 340B covered entity. 24    "340B grantee" means an entity in Illinois that qualifies 25as a covered entity under subparagraphs (A)–(K) of paragraph   10400SB2385sam001- 3 -LRB104 09642 BAB 26633 a1(4) of subsection (a) of Section 340B of the federal Public 2Health Service Act, 42 U.S.C. 256b(a)(4)(A)-(K).3    "Charity care" has the meaning given to that term in line 423 of worksheet 5-10 to the Medicare cost report or in any 5successor form.6    "Children's hospital" has the meaning given to that term 7in Section 5-5.02 of the Illinois Public Aid Code.8    "Critical Access Hospital" has the meaning given to that 9term in paragraph (4) of subsection (b) of Section 5-5e of the 10Illinois Public Aid Code.11    "Hospital" means a hospital licensed under the Hospital 12Licensing Act or University of Illinois Hospital Act.13    "Manufacturer" or "Pharmaceutical Manufacturer" has the 14meaning given to the term "manufacturer" in the Wholesale Drug 15Distribution Licensing Act. 16    "Person" includes a natural person, partnership, 17association, corporation, or any other legal business entity. 18"Person" does not include any federal or State government 19entity or body.20    "Safety-Net Hospital" has the meaning given to that term 21in Section 5-5e.1 of the Illinois Public Aid Code. 22    Section 15. Protection of patient access to pharmacy.23    (a) No person, including a pharmaceutical manufacturer, 24may deny, restrict, prohibit, condition, or otherwise 25interfere with, either directly or indirectly, the acquisition   10400SB2385sam001- 4 -LRB104 09642 BAB 26633 a1of a 340B drug by, or delivery of a 340B drug to, a 340B 2covered entity or a 340B contract pharmacy authorized to 3receive 340B drugs on behalf of the 340B covered entity unless 4the receipt is prohibited by federal law.5    (b) No person, including a pharmaceutical manufacturer, 6may impose any restriction on the ability of a 340B covered 7entity to contract with or designate a 340B contract pharmacy, 8including restrictions relating to the number, location, 9ownership, or type of 340B contract pharmacy.10    (c) Each individual transaction, as defined in 21 U.S.C. 11360eee-24, of 340B drugs that is subject to a prohibited act in 12subsections (a) and (b) shall constitute a separate violation 13of this Act. 14    Section 20. Reporting. On or before August 1, 2026 and 15each August 1 thereafter, a 340B covered entity shall submit a 16report to the General Assembly pursuant to this Section. For 17the purposes of this Section, the following covered entities 18are exempt until January 1, 2028 and will report on or before 19August 1, 2028 and each August 1 thereafter: hospitals with 20fewer than 100 licensed beds, Critical Access Hospitals, 21Safety-Net Hospitals, children's hospitals, and 340B grantees. 22The report must include all of the following for the 340B 23covered entity's 340B program:24        (1) the name of the 340B covered entity submitting the 25    report;  10400SB2385sam001- 5 -LRB104 09642 BAB 26633 a1        (2) a copy of the 340B covered entity's annual 340B 2    program recertification;3        (3) whether a community benefits plan report is 4    required under Section 20 of the Community Benefits Act 5    and, if so, a copy of the 340B covered entity's community 6    benefits plan report;7        (4) the aggregate acquisition cost for prescription 8    drugs obtained under the 340B program and dispensed or 9    administered to patients;10        (5) the aggregate payment amount received for all 11    drugs obtained under the 340B program and dispensed or 12    administered to patients;13        (6) the aggregate payments made to contract pharmacies 14    to dispense drugs obtained under the 340B program;15        (7) the 340B covered entity's total costs for charity 16    care; 17        (8) the number of claims for prescription drugs 18    received under the 340B program;19        (9) the percentage of the 340B covered entity's claims 20    that were for prescription drugs obtained under the 340B 21    program;22        (10) a description of any adverse 340B program audits 23    within the preceding 12 months; and24        (11) a description of the impact of the 340B program 25    on the patients and the community served by the 340B 26    covered entity.   10400SB2385sam001- 6 -LRB104 09642 BAB 26633 a1    Section 25. Medicaid study.2    (a) By January 1, 2028, the Department of Healthcare and 3Family Services shall report to the General Assembly on the 4following for the total aggregated covered outpatient drug 5units dispensed or administered in this State for the prior 6calendar year in connection with the medical assistance 7program under the Illinois Public Aid Code, categorized by (i) 8fee-for-service and (ii) each managed care plan: 9        (1) the number of dispensed or administered covered 10    outpatient drug units; 11        (2) the number of dispensed or administered covered 12    outpatient drug units that were subject to a rebate under 13    42 U.S.C. 1396r-8; and14        (3) a reasonable estimate of net costs or savings to 15    the State's medical assistance program due to 340B covered 16    entity purchases of covered outpatient drug units at 340B 17    pricing. 18    (b) To the extent the Department of Healthcare and Family 19Services lacks information to provide a data element required 20under subsection (a), it shall provide a reasonable estimate 21based on all available information and an explanation of the 22information that it lacks. 23    Section 30. 340B prescription drug applicability. Each 24340B covered entity shall dispense or administer 340B drugs   10400SB2385sam001- 7 -LRB104 09642 BAB 26633 a1only when in connection with an outpatient health care service 2received by the patient within the last 18 months and 3furnished at a registered location of the 340B covered entity. 4    Section 35. Preventing duplication of 340B discounts. Each 5340B covered entity shall develop and maintain a policy that 6ensures it is not placing an order for a 340B drug to replenish 7a prior pharmacy dispense if any other 340B covered entity 8will place an order for a 340B drug to replenish the same prior 9pharmacy dispense. The policy shall also include a process to 10reimburse a manufacturer for any duplicate 340B discount the 11covered entity receives. The policy shall be filed annually 12with the Attorney General. 13    Section 40. Preemption. 14    (a) Nothing in this Act shall be construed or applied to be 15less restrictive than federal law for a person regulated by 16this Act.17    (b) Nothing in this Act shall be construed or applied in a 18manner that would conflict with:19        (1) applicable federal law; or20        (2) other laws of this State if the State law is 21    compatible with applicable federal law.22    (c) Limited distribution of a drug required under 21 23U.S.C. 355-1 may not to be construed as a violation of this 24Act.   10400SB2385sam001- 8 -LRB104 09642 BAB 26633 a1    Section 97. Severability. If any provision of this Act or 2its application to any person or circumstance is held invalid, 3the invalidity of that provision or application does not 4affect other provisions or applications of this Act that can 5be given effect without the invalid provision or application. 6Each paragraph defining "340B contract pharmacy" in Section 10 7is severable. 8    Section 99. Effective date. This Act takes effect upon 9becoming law.".


================================================================================

Raw Text:
Full Text of SB2385 ILGA.GOV SB2385 - 104th General Assembly Sen. David KoehlerFiled: 5/23/2025   10400SB2385sam001LRB104 09642 BAB 26633 a1AMENDMENT TO SENATE BILL 23852    AMENDMENT NO. ______. Amend Senate Bill 2385 by replacing 3everything after the enacting clause with the following: 4    "Section 1. Short title. This Act may be cited as the 5Patient Access to Pharmacy Protection Act. 6    Section 5. Findings. The General Assembly finds that:7    (1) It is within the traditional authority of the State to 8regulate the acquisition and delivery of drugs to pharmacies 9and providers.10    (2) The federal 340B statute is silent on distribution of 11340B-acquired drugs to 340B covered entities and their 12contract pharmacy partners.13    (3) The State's compelling interest in preserving and 14improving access to health care services requires it to ensure 15that 340B covered entities continue to be allowed to contract 16with pharmacies to receive 340B drugs and dispense them to the   10400SB2385sam001- 2 -LRB104 09642 BAB 26633 a1patients of 340B covered entities in accordance with federal 2law.3    (4) Addressing accessibility of these life-saving 4medications is a matter of health, safety, and welfare for the 5people of the State of Illinois. 6    Section 10. Definitions. As used in this Act:7    "340B drug discount program" means the program established 8under Section 340B of the federal Public Health Service Act, 942 U.S.C. 256b.10    "340B contract pharmacy" means any pharmacy that is under 11contract with a 340B covered entity to dispense 340B drugs on 12behalf of the 340B covered entity and is either (i) located in 13Illinois and qualifies as a pharmacy under Section 3 of the 14Pharmacy Practice Act; or (ii) is located in a state, 15commonwealth, or territory of the United States, other than 16Illinois, and dispenses 340B drugs on behalf of the 340B 17covered entity.18    "340B covered entity" means an entity in Illinois that 19qualifies as a covered entity under Section 340B of the 20federal Public Health Service Act, 42 U.S.C. 256b(a)(4).21    "340B drug" means a drug that has been subject to any offer 22for reduced prices by a manufacturer pursuant to 42 U.S.C. 23256b and is purchased by a 340B covered entity. 24    "340B grantee" means an entity in Illinois that qualifies 25as a covered entity under subparagraphs (A)–(K) of paragraph   10400SB2385sam001- 3 -LRB104 09642 BAB 26633 a1(4) of subsection (a) of Section 340B of the federal Public 2Health Service Act, 42 U.S.C. 256b(a)(4)(A)-(K).3    "Charity care" has the meaning given to that term in line 423 of worksheet 5-10 to the Medicare cost report or in any 5successor form.6    "Children's hospital" has the meaning given to that term 7in Section 5-5.02 of the Illinois Public Aid Code.8    "Critical Access Hospital" has the meaning given to that 9term in paragraph (4) of subsection (b) of Section 5-5e of the 10Illinois Public Aid Code.11    "Hospital" means a hospital licensed under the Hospital 12Licensing Act or University of Illinois Hospital Act.13    "Manufacturer" or "Pharmaceutical Manufacturer" has the 14meaning given to the term "manufacturer" in the Wholesale Drug 15Distribution Licensing Act. 16    "Person" includes a natural person, partnership, 17association, corporation, or any other legal business entity. 18"Person" does not include any federal or State government 19entity or body.20    "Safety-Net Hospital" has the meaning given to that term 21in Section 5-5e.1 of the Illinois Public Aid Code. 22    Section 15. Protection of patient access to pharmacy.23    (a) No person, including a pharmaceutical manufacturer, 24may deny, restrict, prohibit, condition, or otherwise 25interfere with, either directly or indirectly, the acquisition   10400SB2385sam001- 4 -LRB104 09642 BAB 26633 a1of a 340B drug by, or delivery of a 340B drug to, a 340B 2covered entity or a 340B contract pharmacy authorized to 3receive 340B drugs on behalf of the 340B covered entity unless 4the receipt is prohibited by federal law.5    (b) No person, including a pharmaceutical manufacturer, 6may impose any restriction on the ability of a 340B covered 7entity to contract with or designate a 340B contract pharmacy, 8including restrictions relating to the number, location, 9ownership, or type of 340B contract pharmacy.10    (c) Each individual transaction, as defined in 21 U.S.C. 11360eee-24, of 340B drugs that is subject to a prohibited act in 12subsections (a) and (b) shall constitute a separate violation 13of this Act. 14    Section 20. Reporting. On or before August 1, 2026 and 15each August 1 thereafter, a 340B covered entity shall submit a 16report to the General Assembly pursuant to this Section. For 17the purposes of this Section, the following covered entities 18are exempt until January 1, 2028 and will report on or before 19August 1, 2028 and each August 1 thereafter: hospitals with 20fewer than 100 licensed beds, Critical Access Hospitals, 21Safety-Net Hospitals, children's hospitals, and 340B grantees. 22The report must include all of the following for the 340B 23covered entity's 340B program:24        (1) the name of the 340B covered entity submitting the 25    report;  10400SB2385sam001- 5 -LRB104 09642 BAB 26633 a1        (2) a copy of the 340B covered entity's annual 340B 2    program recertification;3        (3) whether a community benefits plan report is 4    required under Section 20 of the Community Benefits Act 5    and, if so, a copy of the 340B covered entity's community 6    benefits plan report;7        (4) the aggregate acquisition cost for prescription 8    drugs obtained under the 340B program and dispensed or 9    administered to patients;10        (5) the aggregate payment amount received for all 11    drugs obtained under the 340B program and dispensed or 12    administered to patients;13        (6) the aggregate payments made to contract pharmacies 14    to dispense drugs obtained under the 340B program;15        (7) the 340B covered entity's total costs for charity 16    care; 17        (8) the number of claims for prescription drugs 18    received under the 340B program;19        (9) the percentage of the 340B covered entity's claims 20    that were for prescription drugs obtained under the 340B 21    program;22        (10) a description of any adverse 340B program audits 23    within the preceding 12 months; and24        (11) a description of the impact of the 340B program 25    on the patients and the community served by the 340B 26    covered entity.   10400SB2385sam001- 6 -LRB104 09642 BAB 26633 a1    Section 25. Medicaid study.2    (a) By January 1, 2028, the Department of Healthcare and 3Family Services shall report to the General Assembly on the 4following for the total aggregated covered outpatient drug 5units dispensed or administered in this State for the prior 6calendar year in connection with the medical assistance 7program under the Illinois Public Aid Code, categorized by (i) 8fee-for-service and (ii) each managed care plan: 9        (1) the number of dispensed or administered covered 10    outpatient drug units; 11        (2) the number of dispensed or administered covered 12    outpatient drug units that were subject to a rebate under 13    42 U.S.C. 1396r-8; and14        (3) a reasonable estimate of net costs or savings to 15    the State's medical assistance program due to 340B covered 16    entity purchases of covered outpatient drug units at 340B 17    pricing. 18    (b) To the extent the Department of Healthcare and Family 19Services lacks information to provide a data element required 20under subsection (a), it shall provide a reasonable estimate 21based on all available information and an explanation of the 22information that it lacks. 23    Section 30. 340B prescription drug applicability. Each 24340B covered entity shall dispense or administer 340B drugs   10400SB2385sam001- 7 -LRB104 09642 BAB 26633 a1only when in connection with an outpatient health care service 2received by the patient within the last 18 months and 3furnished at a registered location of the 340B covered entity. 4    Section 35. Preventing duplication of 340B discounts. Each 5340B covered entity shall develop and maintain a policy that 6ensures it is not placing an order for a 340B drug to replenish 7a prior pharmacy dispense if any other 340B covered entity 8will place an order for a 340B drug to replenish the same prior 9pharmacy dispense. The policy shall also include a process to 10reimburse a manufacturer for any duplicate 340B discount the 11covered entity receives. The policy shall be filed annually 12with the Attorney General. 13    Section 40. Preemption. 14    (a) Nothing in this Act shall be construed or applied to be 15less restrictive than federal law for a person regulated by 16this Act.17    (b) Nothing in this Act shall be construed or applied in a 18manner that would conflict with:19        (1) applicable federal law; or20        (2) other laws of this State if the State law is 21    compatible with applicable federal law.22    (c) Limited distribution of a drug required under 21 23U.S.C. 355-1 may not to be construed as a violation of this 24Act.   10400SB2385sam001- 8 -LRB104 09642 BAB 26633 a1    Section 97. Severability. If any provision of this Act or 2its application to any person or circumstance is held invalid, 3the invalidity of that provision or application does not 4affect other provisions or applications of this Act that can 5be given effect without the invalid provision or application. 6Each paragraph defining "340B contract pharmacy" in Section 10 7is severable. 8    Section 99. Effective date. This Act takes effect upon 9becoming law.".